Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Svensson, Harry; Einbeigi, Zakaria; Johansson, Hemming; Hatschek, Thomas; Brandberg, Yvonne

doi:10.1007/s10549-010-1084-8

Cited by 13 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anxiety about the future decreased and emotional functioning also improved. This finding of improved emotional functioning after the start of the treatment is in line with previous studies assessing the quality of life with anthracycline and taxane combinations in metastatic breast cancer [3,8]. According to Ramirez et al, the improvement in emotional functioning might merely reflect the fact that in a life-threatening situation something was being done, irrespective of what it was, and thus it could simply be an indication of hope [19].…”

Section: Discussionsupporting

confidence: 86%

“…Taxane-containing regimens are associated with increased overall survival [2]. Relatively few studies have reported the effect of the combination of anthracyclines and taxanes on the quality of life among women treated first-line for metastatic breast cancer [3][4][5][6][7][8]. Even less is known about the effects of epirubicin and docetaxel combination on the quality of life.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel

Korpela¹,

Mali²,

Kaljonen³

et al. 2011

IJCM

View full text Add to dashboard Cite

This phase II study assessed the clinical response and short-term quality of life of patients receiving first-line chemotherapy with epirubicin-docetaxel combination for metastatic breast cancer. Thirty-one breast cancer patients were treated with epirubicin (75 mg/m<sup>2</sup> for 15 minutes) followed one hour later by a one-hour infusion of docetaxel (75 mg/m<sup>2</sup>) q3w. EORTC QLQ-C30 and EORTC QLQ-BR23 forms were filled in at baseline, and at the second and eighth cycle of chemotherapy. The combination of epirubicin and docetaxel provided a high degree of clinical benefit. Clinical response was observed in 17 patients (55%), including five (16%) complete responses and 12 (39%) partial responses. Of responding and stable patients 23 (74%) maintained the same status for at least six months (clinical benefit). The mean survival time was 40.8 months. During the treatment the emotional functioning improved and the concerns about the future were relieved. Some aspects of quality of life were impaired, with slightly decreased physical and cognitive functioning, distress related to body image and hair loss, and adverse effects of chemotherapy. Overall, the global quality of life was maintained

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel

Korpela¹,

Mali²,

Kaljonen³

et al. 2011

IJCM

View full text Add to dashboard Cite

show abstract

“…Some studies investigating combined targeted therapies (eg, lapatinib plus trastuzumab vs lapatinib alone) reported small, nonsignificant HRQOL benefits,28 but these effects are inconsistent. In other studies, adverse events attributable to breast cancer treatment (such as the TEX [epirubicin, paclitaxel, and capecitabine] regimen) had a detrimental impact on HRQOL 29. Symptom clusters such as pain, fatigue, insomnia, and mood disturbances are prevalent in patients after cancer treatment, particularly chemotherapy and radiotherapy, and can adversely affect QOL and functional status 30.…”

Section: Discussionmentioning

confidence: 99%

Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial

Burris

Lebrun

Rugo

et al. 2013

Cancer

View full text Add to dashboard Cite

BACKGROUND:The randomized, controlled BOLERO-2 (Breast Cancer Trials of Oral Everolimus) trial demonstrated significantly improved progression-free survival with the use of everolimus plus exemestane (EVE þ EXE) versus placebo plus exemestane (PBO þ EXE) in patients with advanced breast cancer who developed disease progression after treatment with nonsteroidal aromatase inhibitors. This analysis investigated the treatment effects on health-related quality of life (HRQOL). METHODS: Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) questionnaire, HRQOL was assessed at baseline and every 6 weeks thereafter until disease progression and/or treatment discontinuation. The 30 items in 15 subscales of the QLQ-C30 include global health status wherein higher scores (range, 0-100) indicate better HRQOL. This analysis included a protocol-specified time to definitive deterioration (TDD) analysis at a 5% decrease in HRQOL versus baseline, with no subsequent increase above this threshold. The authors report additional sensitivity analyses using 10-point minimal important difference decreases in the global health status score versus baseline. Treatment arms were compared using the stratified log-rank test and Cox proportional hazards model adjusted for trial stratum (visceral metastases, previous hormone sensitivity), age, sex, race, baseline global health status score and Eastern Cooperative Oncology Group performance status, prognostic risk factors, and treatment history. RESULTS: Baseline global health status scores were found to be similar between treatment groups (64.7 vs 65.3). The median TDD in HRQOL was 8.3 months with EVE þ EXE versus 5.8 months with PBO þ EXE (hazard ratio, 0.74; P ¼.0084). At the 10-point minimal important difference, the median TDD with EVE þ EXE was 11.7 months versus 8.4 months with PBO þ EXE (hazard ratio, 0.80; P ¼.1017). CONCLUSIONS: In patients with advanced breast cancer who develop disease progression after treatment with nonsteroidal aromatase inhibitors, EVE þ EXE was associated with a longer TDD in global HRQOL versus PBO þ EXE. Cancer 2013;119:1908-15.

show abstract

“…Ten studies reported adverse events including gastrointestinal problems, 31 , 32 , 43 , 53 dizziness, 31 , 32 changes in blood pressure, 31 , 34 , 60 weakness, 31 anemia, 32 pain/discomfort, 24 , 34 , 47 headache, 43 , 60 insomnia, 53 palpitations, 53 anxiety, 53 skin rashes and angioedema, 51 jaundice/liver damage, 51 dry mouth, 21 changes in taste, 21 , 51 and disease progression. 24 Additionally, two studies 22 , 23 reported adverse events occurred but did not describe them.…”

Section: Resultsmentioning

confidence: 99%

Are there efficacious treatments for treating the fatigue–sleep disturbance–depression symptom cluster in breast cancer patients? A Rapid Evidence Assessment of the Literature (REAL©)

Jain

Boyd²,

Fiorentino

et al. 2015

BCTT

View full text Add to dashboard Cite

PurposeWhile fatigue, sleep disturbance, and depression often co-occur in breast cancer patients, treatment efficacy for this symptom cluster is unknown. A systematic review was conducted to determine whether there are specific interventions (ie, medical, pharmacological, behavioral, psychological, and complementary medicine approaches) that are effective in mitigating the fatigue–sleep disturbance–depression symptom cluster in breast cancer patients, using the Rapid Evidence Assessment of the Literature (REAL©) process.MethodsPeer-reviewed literature was searched across multiple databases; from database inception – October 2011, using keywords pre-identified to capture randomized controlled trials (RCT) relevant to the research question. Methodological bias was assessed using the Scottish Intercollegiate Guidelines Network (SIGN) 50 checklist. Confidence in the estimate of effect and assessment of safety were also evaluated across the categories of included interventions via the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology.ResultsThe initial search yielded 531 citations, of which 41 met the inclusion criteria. Of these, twelve RCTs reported on all three symptoms, and eight of these were able to be included in the GRADE analysis. The remaining 29 RCTs reported on two symptoms. Studies were of mixed quality and many were underpowered. Overall, results suggest that there is: 1) promising evidence for the effectiveness of various treatment types in mitigating sleep disturbance in breast cancer patients; 2) mixed evidence for fatigue; 3) little evidence for treating depression; and 4) no clear evidence that treatment of one symptom results in effective treatment for other symptoms.ConclusionMore high-quality studies are needed to determine the impact of varied treatments in mitigating the fatigue–sleep disturbance–depression symptom cluster in breast cancer patients. Furthermore, we encourage future studies to examine the psychometric and clinical validity of the hypothesized relationship between the symptoms in the fatigue–sleep disturbance–depression symptom cluster.

show abstract

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Abstract: ity of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).

Cited by 13 publications

References 19 publications

Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel

Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel

Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial

Are there efficacious treatments for treating the fatigue–sleep disturbance–depression symptom cluster in breast cancer patients? A Rapid Evidence Assessment of the Literature (REAL©)

Contact Info

Product

Resources

About

Quality of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine)

Abstract: ity of life in women with metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin and paclitaxel w/o capecitabine).

Cited by 13 publications

References 19 publications

Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel

Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel

Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial

Are there efficacious treatments for treating the fatigue&ndash;sleep disturbance&ndash;depression symptom cluster in breast cancer patients? A Rapid Evidence Assessment of the Literature (REAL&copy;)

Contact Info

Product

Resources

About

Are there efficacious treatments for treating the fatigue–sleep disturbance–depression symptom cluster in breast cancer patients? A Rapid Evidence Assessment of the Literature (REAL©)